EQT Life Sciences, a European life sciences and healthcare venture capital firm, and OrbiMed, a healthcare investment firm, led a €54m Series B round in MinervaX, a Danish biotechnology company, with participation from Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest. "EQT Life Sciences is thrilled to take an active part in the MinervaX prophylactic vaccine against GBS with the hope to save newborns' lives. We are impressed by the clinical data achieved so far, the quality of the team and the near-term milestones enabling MinervaX to start a registration trial," Vincent Brichard, EQT Life Sciences Venture Partner.